GlassScriptPhysician profile
Firas Khamis
NPI 1205164969
$2,887.69
in general payments reported to CMS, 2019-2025
31 companies · $70.00 in 2025
The $70.00 reported for 2025 was less than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $362 · 2020: $291 · 2021: $185 · 2022: $335 · 2023: $561 · 2024: $1,084 · 2025: $70.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,714.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $411.08 | 2019-2024 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $376.86 | 2023-2024 | Fasenra, Airsupra, Breztri |
| Regeneron Healthcare Solutions, INC. | $304.35 | 2022-2024 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $259.13 | 2019-2024 | Stiolto Respimat, Spiriva Respimat |
| Janssen Pharmaceuticals, INC | $251.19 | 2020-2021 | |
| Glaxosmithkline, LLC. | $115.58 | 2019-2024 | Nucala, Trelegy Ellipta |
| Lantheus Medical Imaging, INC. | $111.74 | 2022 | |
| Merck Sharp & Dohme LLC | $109.99 | 2022-2024 | Keytruda, Dificid, Zerbaxa |
| Abbvie INC. | $102.82 | 2022-2024 | |
| Genzyme Corporation | $102.13 | 2020-2024 | |
| Electromed, INC. | $100.47 | 2023-2024 | Smartvest |
| Astellas Pharma US INC | $90.89 | 2019-2021 | |
| Amgen INC. | $69.55 | 2024 | Tezspire |
| Alexion Pharmaceuticals, INC. | $57.89 | 2020-2023 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $57.76 | 2019-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $45.72 | 2024 | Arikayce |
| Boston Scientific Corporation | $37.84 | 2025 | Watchman Flx |
| Verona Pharma, INC. | $32.16 | 2025 | Ohtuvayre |
| United Therapeutics Corporation | $31.98 | 2019 | |
| Mallinckrodt Hospital Products INC. | $24.76 | 2020 | |
| Inogen, INC. | $24.32 | 2024 | |
| Gilead Sciences, INC. | $23.11 | 2024 | Veklury |
| Genentech USA, INC. | $22.09 | 2023 | Xolair |
| Pharming Healthcare, INC. | $17.53 | 2024 | Ruconest |
| Shionogi INC | $17.14 | 2024 | Fetroja |
| Olympus America INC. | $17.01 | 2023 | Olympus |
| Portola Pharmaceuticals, LLC | $16.68 | 2020 | |
| Csl Behring | $15.76 | 2019 | |
| Philips North America LLC | $15.12 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $13.12 | 2021 | |
| Covidien LP | $11.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Firas Khamis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.